|
|
 | | | |
- close
- close
- close
- close
UCB SA (UCB-BT) |
Benzinga
Jun 13
Comment
Immunomedics, Inc.
(Nasdaq: IMMU),a biopharmaceutical company primarily focused on the development
of monoclonal antibody-based products for the targeted treatment of cancer,
autoimmune and other serious diseases, today reported that UCB...
FiercePharma
May 29
Comment
he sale to France-based Unither includes a 6-year supply deal, and the buyer plans to keep UCB's 250 employees and 50 contract workers.
Mondo Visione
Mar 27
Comment
NYSE Euronext (NYX) today announced a successful €250 million bond issue on its Brussels-market by UCB, the Belgium-based global biopharmaceutical group.
UCB focuses on the discovery and development of innovative medicines and solutions to...
Stock Blog Hub
Mar 5
Comment
UCB (UCBJF) recently announced that it has licensed exclusive global rights to tozadenant (SYN115) for Parkinson’s disease from Biotie Therapies.
The Candidate
Tozadenant is an orally administered, selective inhibitor of the adenosine 2a...
FiercePharma
Feb 21
Comment
Pfizer's attempts to prove Lyrica effective as an epilepsy treatment have delivered mixed results. Just three months ago, the controlled-release formula failed a Phase III trial in adults with epilepsy. But now, the company ($PFE) has unveiled new...
StreetInsider.com
Jan 8
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/UCB+%28UCBA%29+to+Announces+Share+Conversion+as+Preps+to+Become+Stock+Holding+Co./7994825.html for the full story.
MedPage Today
Nov 14
Comment
WASHINGTON (MedPage Today) -- Treatment with the tumor necrosis factor inhibitor certolizumab pegol (Cimzia) led to significant improvements in the symptoms and signs of axial spondyloarthritis, a researcher reported here.
FierceBiotech
Sep 28
Comment
Just as good isn't good enough in many biopharma circles, Brussels-based drugmaker UCB hit the primary efficacy goal of its Phase IIb trial of an antibody drug against rheumatoid arthritis, but the future of the program is up in the air after the...
FiercePharma
Aug 1
Comment
There's a bumper crop of numbers today as pharma's earnings season winds down. The dominant trends continue--the stronger dollar, generic competition (for branded drugmakers), new copycat products (for generics firms) and lots of...
StreetInsider.com
Jul 25
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Endo%27s+%28ENDP%29+Qualitest+Receives+FDA+Approval+for+Generic+Keppra+XR+NDA/7602321.html for the full story.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
| |||||||
